留尼汪岛幽门螺杆菌对克拉霉素的耐药性
Helicobacter pylori resistance to clarithromycin in Reunion Island.
作者信息
Zemali N, Guillemot G, Jaubert J, Picot S, Thomas E, Becquart J P, Camuset G, Gérardin P, Michault A, Kwiatek S
机构信息
Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion.
Service de gastro-entérologie, CHU de La Réunion, 97410 Saint-Pierre, Reunion.
出版信息
Med Mal Infect. 2016 Oct;46(7):385-389. doi: 10.1016/j.medmal.2016.06.004. Epub 2016 Jul 15.
OBJECTIVE
The increasing resistance of Helicobacter pylori to clarithromycin led to developing new eradication treatment regimens. The objective of our observational study was to determine the proportion of H. pylori strains resistant to clarithromycin in infected patients in Reunion Island and to suggest a first-line treatment in agreement with the local ecology.
PATIENTS AND METHODS
We included 200 patients who underwent esophagogastroduodenoscopy at the University Hospital of Saint-Pierre from February to July 2014. H. pylori was isolated from 73 patients.
RESULTS
A wild-type susceptibility profile to clarithromycin was observed in 64 isolates (87.7%) and nine isolates (12.3%) had a resistant mutation profile.
CONCLUSION
With a proportion of resistant strains below the critical threshold of 15%, physicians in Reunion Island may continue to prescribe the usual treatment regimen as a first-line option (clarithromycin, amoxicillin, and proton pump inhibitor for 14 days).
目的
幽门螺杆菌对克拉霉素的耐药性不断增加，促使人们开发新的根除治疗方案。我们这项观察性研究的目的是确定留尼汪岛感染患者中对克拉霉素耐药的幽门螺杆菌菌株比例，并根据当地生态情况提出一线治疗方案。
患者与方法
我们纳入了2014年2月至7月在圣皮埃尔大学医院接受食管胃十二指肠镜检查的200例患者。从73例患者中分离出幽门螺杆菌。
结果
64株（87.7%）对克拉霉素呈现野生型药敏谱，9株（12.3%）具有耐药突变谱。
结论
由于耐药菌株比例低于15%的临界阈值，留尼汪岛的医生可继续将常规治疗方案（克拉霉素、阿莫西林和质子泵抑制剂，疗程14天）作为一线选择。
Zotero 插件